LifePoint Hospitals initiated with an Outperform at Imperial Capital Imperial views LifePoint Hospitals as an attractive leveraged buyout candidate with the potential to be taken private at a 42% premium to the current share price. The firm started shares with an Outperform rating and $53 price target.
LifePoint Hospitals upgraded at RW Baird As previously reported, Baird upgraded LifePoint to Outperform from Neutral. The firm upgraded shares based on valuation, M&A pipeline momentum, improved core operations, and potential further ACA benefit. Price target raised to $76 from $70.